About us
ABOUT US
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.
READ MORE
Company Overview

Management
Board of Directors
Diversity in the Board
Board Evaluation

Corporate Governance
Board Committees
Remuneration Policy
Articles of Association
Corporate Social Responsibility
What we do
WHAT WE DO
Bavarian Nordic focuses on developing product candidates to address cancer and infectious diseases.
READ MORE
Products
Pipeline
Technology
MVA-BN
Manufacturing
CDMO Services

Infectious Diseases
Smallpox
Monkeypox
RSV
Ebola
Equine encephalitis
HPV
Cancer Immunotherapy
Chordoma

Clinical Trials
Expanded Access Policy
Publications
Posters
INVESTORS
INVESTORS
Bavarian Nordic is committed to providing our shareholders and the media with reliable and transparent information about our business, development programs and results in an open and timely manner
Read more
News
Subscribe
Events & Presentations
Downloads
Financial Reports
CSR Reports
Image Archive

Share Information
Stock Chart
Analysts
Ownership
ADR Program

Annual Report 2019
Shareholder Portal
FAQ
Contact
IR Policy
Careers
CAREERS
Bavarian Nordic offers a challenging international working environment in which
job satisfaction and personal growth have a high priority.
READ MORE
Working With Us
Our Values
Our Employee Philosophy
Our Code of Ethics

Our Employees

The Recruitment Process
Privacy Notice for Applicants
Job Openings
For Students

Clinical Trials

Bavarian Nordic and its partners conduct clinical studies of its vaccine candidates to evaluate their safety and efficacy.

Clinical studies that are actively enrolling patients or are planned are detailed below.

Clinical trials with CV301Clinical trials with CV301

Ongoing or planned trials

Phase 2 Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer Location: USA Read more: NCT03547999
A Phase 1/2 Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma Location: USA Read more: NCT03376659

Clinical trials with BN-BrachyuryClinical trials with BN-Brachyury

Ongoing or planned trials

Phase 1/2 Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1) Location: USA Read more: NCT03493945